首页> 外文期刊>Nuclear Medicine and Biology >Method for stabilizing non carrier added 2-((18)F)fluoromethyl-l-phenylalanine, a new tumour tracer, during radiosynthesis and radiopharmaceutical formulation.
【24h】

Method for stabilizing non carrier added 2-((18)F)fluoromethyl-l-phenylalanine, a new tumour tracer, during radiosynthesis and radiopharmaceutical formulation.

机译:在放射合成和放射性药物制剂过程中稳定非载体的方法增加了2-((18)F)氟甲基-1-苯基丙氨酸,一种新型的肿瘤示踪剂。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION: Non carrier added (NCA) 2-[(18)F]fluoromethyl-l-phenylalanine is currently used in a Phase I study. Improvement of the stability of the fluorobenzyl analogue, very sensitive to defluorination and hydrolysis, during the synthetic route and in the radiopharmaceutical formulation was devised. METHODS: The protected brominated precursor was synthesised in three steps. The labelling with [(18)F(-)] occurred in acetonitrile using K(2)CO(3)/K(2.2.2) (120 degrees C, 5 min). NCA 3-(2-[(18)F(-)]Fluoromethyl-phenyl)-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester recovered from HPLC was submitted to deprotection in TFA/CH(2)Cl(2) in the presence of CaCl(2). After evaporation and adsorption on a mini C18 column, the tracer was recovered in 4 ml of H(2)O. Appropriate amounts of CaCl(2) and NaCl solutions were added for isotonic formulation, and this solution was sterilised by a 0.2-microm Cathivex filter. Shelf-life stability in the presence of Ca(2+) and Mg(2+) ions was studied. Stereoisomeric purity was checked by chiral HPLC. RESULTS: The labelling showed a reproducible labelling yield of at least 90%. The followed strategy and the presence of Ca(2+) ions during deprotection, minimizing the loss of [(18)F(-)] from the labile fluorobenzyl group, allowed to obtain a decay-corrected yield of 75%. No racemisation was observed. The radiopharmaceutical formulation containing 0.04 M CaCl(2) allows a shelf-life of about 6 h without significant radiodefluorination. CONCLUSION: The described synthetic route yields 40% of radiochemical pure NCA 2-[(18)F]fluoromethyl-l-phenylalanine within 105 min. A solution was found to reduce considerably the radiodefluorination. Addition of CaCl(2) prior to deprotection limits the loss of radiofluoride to less than 10%. The calcium ions present in the final radiopharmaceutical formulation (0.04 M) assure a shelf-life of at least 6 h.
机译:简介:目前,I期研究使用的是非载体添加(NCA)2-[((18)F]氟甲基-1-苯丙氨酸)。设计了在合成路线中和在放射性药物制剂中改进对脱氟和水解非常敏感的氟苄基类似物的稳定性。方法:分三个步骤合成了受保护的溴化前体。在[[18] F(-)]的乙腈中使用K(2)CO(3)/ K(2.2.2)进行标记(120摄氏度,5分钟)。从HPLC中回收的NCA 3-(2-[((18)F(-)]氟甲基-苯基)-2-叔丁氧基羰基氨基-丙酸叔丁酯在TFA / CH(2)Cl(2)中脱保护在CaCl(2)存在下。蒸发并吸附在微型C18色谱柱上后,示踪剂回收到4 ml的H(2)O中。为等渗配方添加适量的CaCl(2)和NaCl溶液,并用0.2微米的Cathivex过滤器对该溶液进行灭菌。研究了Ca(2+)和Mg(2+)离子存在下的保质期稳定性。通过手性HPLC检查立体异构体纯度。结果:标记显示可重复的标记产率至少为90%。遵循的策略以及在脱保护过程中Ca(2+)离子的存在,使不稳定的氟苄基基团的[(18)F(-)]损失降至最低,从而获得了75%的衰减校正产率。没有观察到外消旋作用。含有0.04 M CaCl(2)的放射性药物制剂的货架期约为6小时,而无明显的放射性脱氟。结论:所描述的合成路线在105分钟内可产生40%的放射化学纯NCA 2-[((18)F]氟甲基-1-苯基丙氨酸)。发现一种溶液可大大减少放射性脱氟。脱保护前添加CaCl(2)可将放射性氟化物的损失限制在10%以下。最终放射性药物制剂(0.04 M)中存在的钙离子可确保至少6小时的保存期限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号